Brookline Capital Markets initiated coverage of Medicus Pharma (NASDAQ:MDCX) with a buy rating, citing the potential of its ...

Medicus Pharma Ltd. has announced a change in its auditing firm, with MNP LLP resigning and EisnerAmper LLP being appointed as the new auditor. The transition, effective December 19, 2024, was ...

Medicus Pharma Ltd (MDCX) has received a new Buy rating, initiated by Brookline Capital Markets analyst, Kumaraguru Raja.Don't Miss Our ...

Medicus Pharma Ltd. has announced that its Investigational New Animal Drug for a dissolvable Doxorubicin-containing microneedle array (D-MNA) has received Minor Use in Major Species Designation ...

Company to Submit Product Development Plan to Treat External Squamous Cell Carcinoma (SCC) in HorsesTORONTO and PHILADELPHIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ ...

TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce an agreement with Swanielle Inc. (“Swanielle”) to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Brookline analyst Kumaraguru Raja initiated coverage of Medicus Pharma (MDCX) with a Buy rating and $12 price target Medicus is advancing D-MNA, a doxorubicin tip loaded dissolvable microarray ...